Advances in the prevention, management, and treatment of community-acquired pneumonia.
F1000Res. 2016 Mar 8;5.
Pletz MW1, Rohde GG2, Welte T3, Kolditz M4, Ott S5.
1Center for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany.
2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
3Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, Netherlands.
4Division of Pulmonology, University Hospital Carl Gustav Carus, Dresden, Germany.
5Department of Pulmonary Medicine, Inselspital, University Hospital, Bern, Switzerland.
Community-acquired pneumonia (CAP) is the infectious disease with the highest number of deaths worldwide. Nevertheless, its importance is often underestimated.
Large cohorts of patients with CAP have been established worldwide and improved our knowledge about CAP by far.
Therefore, current guidelines are much more evidence-based than ever before.
This article discusses recent major studies and concepts on CAP such as the role of biomarkers, appropriate risk stratification to identify patients in need of hospitalisation or intensive care, appropriate empiric antibiotic therapy (including the impact of macrolide combination therapy and antibiotic stewardship), and CAP prevention with novel influenza and pneumococcal vaccines.
Methicillin-resistant S. aureus (MRSA), extended-spectrum (ESBL)- and plasmid-mediated AmpC ß-lactamase -producing Gram-negative bacteria associated with skin and soft tissue infections in hospital and community settings. Application of Mass Spectrometry Technology to Early Diagnosis of Invasive Fungal Infections